Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Vangsted · SciRah

Researcher profile · Semantic Scholar

A. Vangsted

Share profile

A. Vangsted — researcher profile on SciRah

h-index: 31
Works: 191
Citations: 4,354

Most-cited papers

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
P. Sonneveld, M. Dimopoulos, M. Boccadoro, H. Quach +39 more
2023New England Journal of Medicine477 citations Open access
Semantic Scholar
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
P. Moreau, Shaji K. Kumar, J. S. San Miguel, F. Davies +66 more
2021The Lancet Oncology220 citations Open access
Semantic Scholar
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
E. Terpos, M. Engelhardt, G. Cook, F. Gay +14 more
2020Leukemia124 citations Open access
Semantic Scholar
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
M. Went, A. Sud, A. Försti, Britta Halvarsson +127 more
2018Nature Communications108 citations Open access
Semantic Scholar
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
N. Bahlis, R. Baz, S. Harrison, H. Quach +11 more
2021Journal of Clinical Oncology79 citations Open access
Semantic Scholar
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
P. Richardson, S. Trudel, R. Popat, M. Mateos +27 more
2023New England Journal of Medicine70 citations Open access
Semantic Scholar
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
E. Terpos, P. Musto, M. Engelhardt, M. Delforge +17 more
2023Leukemia45 citations Open access
Semantic Scholar
The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials
T. Klausen, H. Gregersen, N. Abildgaard, N. F. Andersen +4 more
2018Leukemia42 citations Open access
Semantic Scholar
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
M. Pertesi, M. Vallée, Xiaomu Wei, M. Revuelta +88 more
2019Leukemia41 citations Open access
Semantic Scholar
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
P. Musto, M. Engelhardt, J. Caers, N. Bolli +20 more
2021Haematologica40 citations Open access
Semantic Scholar
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
P. Richardson, A. Vangsted, K. Ramasamy, S. Trudel +16 more
202028 citations
Semantic Scholar
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
N. V. van de Donk, M. Minnema, B. van der Holt, F. Schjesvold +24 more
2023The Lancet Oncology27 citations Open access
Semantic Scholar
Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
Kari Lenita Falck Moore, I. Turesson, A. Genell, T. Klausen +6 more
2022Haematologica25 citations Open access
Semantic Scholar
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
T. Plesner, S. Harrison, H. Quach, Cindy H. S. Lee +14 more
2023Clinical Hematology International23 citations Open access
Semantic Scholar
The real-world outcomes of multiple myeloma patients treated with daratumumab
A. Szabo, T. Klausen, M. Levring, B. Preiss +14 more
2021PLoS ONE23 citations Open access
Semantic Scholar
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry
L. Redder, T. Klausen, A. Vangsted, H. Gregersen +12 more
2020British Journal of Haematology20 citations Open access
Semantic Scholar
Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study
N. V. van de Donk, B. van der Holt, F. Schjesvold, K. Wu +18 more
2019Blood20 citations Open access
Semantic Scholar
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
C. Blimark, A. Vangsted, T. Klausen, H. Gregersen +6 more
2021European Journal of Haematology18 citations Open access
Semantic Scholar
Genetically determined telomere length and multiple myeloma risk and outcome
M. Giaccherini, A. Macauda, E. Orciuolo, M. Rymko +45 more
2021Blood Cancer Journal17 citations Open access
Semantic Scholar
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
H. Gregersen, Valdas Pečeliūnas, K. Remes, F. Schjesvold +17 more
2021European Journal of Haematology17 citations Open access
Semantic Scholar
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
P. Sonneveld, M. Dimopoulos, M. Boccadoro, H. Quach +39 more
2023Blood15 citations Open access
Semantic Scholar
Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study
A. Szabo, J. Thorsen, K. F. Iversen, C. T. Hansen +10 more
2020American journal of hematology/oncology15 citations Open access
Semantic Scholar
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients
A. Macauda, E. Castelli, G. Buda, M. Pelosini +27 more
2018British Journal of Haematology15 citations Open access
Semantic Scholar
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
D. Campa, A. Martino, A. Macauda, M. Dudzinski +43 more
2019Leukemia and Lymphoma14 citations Open access
Semantic Scholar
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
E. Clavero, J. M. Sánchez-Maldonado, A. Macauda, R. ter Horst +68 more
2023International Journal of Molecular Sciences13 citations Open access
Semantic Scholar
A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
T. Plesner, S. Harrison, H. Quach, Cindy H. S. Lee +13 more
2021Blood13 citations Open access
Semantic Scholar
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
J. Kaufman, R. Baz, S. Harrison, H. Quach +13 more
202013 citations
Semantic Scholar
Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study
N. Bahlis, H. Quach, R. Baz, A. Vangsted +10 more
2023Blood12 citations
Semantic Scholar
Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
L. Wong, M. Lamba, Maria D. Jimenez-Nuñez, D. Bauer +16 more
202012 citations Open access
Semantic Scholar
A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
H. Gregersen, T. Do, I. Kristensen, U. Frølund +6 more
2018Experimental Hematology & Oncology12 citations Open access
Semantic Scholar
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
L. Bertamini, C. Fokkema, P. Rodríguez-Otero, M. van Duin +22 more
2025Blood11 citations Open access
Semantic Scholar
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease
P. Richardson, M. Mateos, A. Vangsted, K. Ramasamy +4 more
2022Espert Review of Proteomics11 citations
Semantic Scholar
Clarithromycin added to the VCD regimen causes reduced health-related quality of life in multiple myeloma patients
L. K. Nielsen, T. Klausen, I. Kristensen, U. Frølund +5 more
201811 citations Open access
Semantic Scholar
A polygenic risk score for multiple myeloma risk prediction
F. Canzian, Chiara Piredda, A. Macauda, D. Zawirska +36 more
2021European Journal of Human Genetics10 citations Open access
Semantic Scholar
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
A. Macauda, Chiara Piredda, A. Clay-Gilmour, J. Sainz +50 more
2021International Journal of Cancer10 citations Open access
Semantic Scholar
First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
N. Bahlis, R. Baz, S. Harrison, H. Quach +12 more
2019Blood10 citations Open access
Semantic Scholar
Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts
Ankita Agrawal, L. Kruse, A. Vangsted, A. Gartland +1 more
2020Cells9 citations Open access
Semantic Scholar
Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients
L. K. Nielsen, T. Klausen, M. Jarden, H. Frederiksen +7 more
2018European Journal of Haematology9 citations Open access
Semantic Scholar
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
J. N. Nørgaard, N. Abildgaard, A. Lysén, G. Tsykunova +9 more
2023Leukemia8 citations
Semantic Scholar
Potential value of pre-planned imaging of bone disease in multiple myeloma
M. Gundesen, J. Asmussen, F. Schjesvold, A. Vangsted +10 more
2023Blood Cancer Journal6 citations Open access
Semantic Scholar
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy
A. Szabo, J. Thorsen, K. F. Iversen, M. Levring +14 more
2021American journal of hematology/oncology6 citations
Semantic Scholar
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
M. Went, A. Sud, A. Försti, Britta Halvarsson +65 more
2019Nature Communications6 citations Open access
Semantic Scholar
An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
J. Kaufman, H. Quach, R. Baz, A. Vangsted +11 more
2022Blood5 citations Open access
Semantic Scholar
Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
J. Kaufman, H. Quach, R. Baz, A. Vangsted +12 more
2021Blood5 citations Open access
Semantic Scholar
A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group
H. Gregersen, Valdas Pečeliūnas, K. Remes, F. Schjesvold +16 more
2019Blood5 citations Open access
Semantic Scholar
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
Mads Harsløf, Iman Chanchiri, T. Silkjær, U. Frølund +10 more
2024eJHaem4 citations Open access
Semantic Scholar
Large differencies in age-specific survival in multiple myeloma in the nordic countries
K. Hemminki, F. Zitricky, A. Försti, R. Silvennoinen +2 more
2024Blood Cancer Journal4 citations Open access
Semantic Scholar
Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Pers
L. Bertamini, C. Fokkema, P. Rodríguez-Otero, M. van Duin +22 more
2024Blood4 citations
Semantic Scholar
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
A. Szabo, J. Thorsen, K. F. Iversen, M. Levring +8 more
2023eJHaem4 citations Open access
Semantic Scholar
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
A. Szabo, T. Klausen, N. Abildgaard, H. Gregersen +7 more
2021Blood Cancer Journal4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Abildgaard×16
Invite
N. Abildgaard — researcher profile on SciRah
H. Quach×13
Invite
H. Quach — researcher profile on SciRah
N. Bahlis×11
Invite
N. Bahlis — researcher profile on SciRah
N. V. van de Donk×10
Invite
N. V. van de Donk — researcher profile on SciRah

×10

Invite

N. F. Andersen — researcher profile on SciRah

Invite

P. Moreau — researcher profile on SciRah

F. Schjesvold×9

Invite

F. Schjesvold — researcher profile on SciRah

Invite

F. Canzian — researcher profile on SciRah

H. Gregersen×9

Invite

H. Gregersen — researcher profile on SciRah

Invite

U. Frølund — researcher profile on SciRah

C. Helleberg×9

Invite

C. Helleberg — researcher profile on SciRah

M. Boccadoro×8

Invite

M. Boccadoro — researcher profile on SciRah